p.83 抽出テキスト

Recommendations for patients with coronary artery disease Aspirin 75100 mg daily is recommended for patients with a previous myocardial infarction or revascularization. I A In ACS, DAPT with a P2Y12 inhibitor in addition to aspirin is recommended for 12 months, unless there are contraindications such as excessive risk of bleeding. I A In patients with CCS, clopidogrel 75 mg daily is recommended, in addition to aspirin, for 6 months following coronary stenting, irrespective of stent type, unless a shorter duration (13 months) is indicated due to risk or the occurrence of life-threatening bleeding. I A ACE inhibitors (or ARB) are recommended if a patient has other conditions (e.g. HF, hypertension, or DM). I A Beta-blockers are recommended in patients with LV dysfunction or systolic HF. I A In patients with established ASCVD, oral lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >_50% reduction in LDL-C vs. baseline is recommended. I A Recommendations regarding pharmacological and nonpharmacological interventions for patients with symptomatic (New York Heart Association class II-IV) heart failure with reduced ejection fraction (left ventricular ejection fraction <40%) with proven benefits on clinical outcomes, including cardiovascular morbidity and mortality It is recommended that patients with HF are enrolled in a comprehensive CR programme to reduce the risk of HF hospitalization and death. I A EBCR is recommended in stable symptomatic patients with HFrEF to reduce the risk of HF hospitalization. I A It is recommended to screen patients with HF for both CV and non-CV comorbidities, which, if present, should be treated, provided safe and effective interventions exist, not only to alleviate symptoms but also to improve prognosis. I A An ACE inhibitor is recommended, in addition to a beta-blocker and an MRA, for patients with symptomatic HFrEF to reduce the risk of HF hospitalization and death. I A A beta-blocker is recommended, in addition to an ACE inhibitor (or an ARNI) and an MRA, for patients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death. I A An MRA is recommended for patients with HFrEF already treated with an ACE inhibitor (or an ARNI) and a beta-blocker, to reduce the risk of HF hospitalization and death. I A Sacubitril/valsartan is recommended as a replacement for an ACE inhibitor to reduce the risk of HF hospitalization and death in patients with HFrEF. I B An ARB is recommended to reduce the risk of HF hospitalization or CV death in symptomatic patients with HFrEF who are unable to tolerate an ACE inhibitor and/or ARNI (patients should also receive a beta-blocker and an MRA). I B Dapagliflozin or empagliflozin are recommended, in addition to optimal treatment of an ACE inhibitor (or ARNI), a beta-blocker, and an MRA, for patients with HFrEF to reduce the risk of HF hospitalization and death. I A Diuretics are recommended in patients with HFrEF with signs and/or symptoms of congestion to reduce the risk of HF hospitalization. I C Recommendations for patients with cerebrovascular disease In patients with a cerebrovascular event, improvement of lifestyle factors in addition to appropriate pharmacological management is recommended. I A In patients with ischaemic stroke or TIA, prevention with antithrombotics is recommended; choice of antithrombotic depends on the mechanism of event. Use of an antiplatelet is recommended for patients with non-cardioembolic ischaemic stroke or TIA, and use of an anticoagulant is recommended in patients with cardioembolic ischaemic stroke or TIA. I A In patients with non-cardioembolic ischaemic stroke or TIA, prevention with aspirin only, or dipyridamole plus aspirin, or clopidogrel alone is recommended. I A In patients with stroke or TIA who have BP of 140/90 mmHg or higher, BP lowering is recommended. I A Recommendations for patients with lower extremity artery disease: best medical therapy Smoking cessation is recommended in all patients with LEAD. I B Healthy diet and PA are recommended for all patients with LEAD. I C In patients with intermittent claudication: • Supervised exercise training is recommended I A

• Non-supervised exercise training is recommended when supervised exercise training is not feasible or available. I C

Antiplatelet therapy is recommended in patients with symptomatic LEAD. I C In patients with LEAD and hypertension, it is recommended to control BP at <140/90 mmHg. I A In patients with LEAD and DM, strict glycaemic control is recommended. I A

Continued Downloaded from academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 07 October 2026